Sorrento Therapeutics Inc (OTC Pink - Current Information:SRNEQ)
| 0.3251 Delayed Data As of 12:00am ET |  -0.0149 / -4.38%Today’s Change | 0.16 Today|||52-Week Range 3.09 | -63.31% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $187.4M |
Company Description
Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
Contact Information
Sorrento Therapeutics, Inc. 4955 Directors Place San Diego California 92121 |
Employees
Shareholders
| Individual stakeholders | 8.18% |
| Mutual fund holders | 7.61% |
| Other institutional | 12.22% |
Top Executives
| Henry H. Ji | Chairman, President & Chief Executive Officer |
| Shawn Sahebi | Senior Vice President-Commercial Operations |
| Elizabeth Adkins Czerepak | Chief Financial & Business Officer, Executive VP |
| Mike A. Royal | Chief Medical Officer |
| Robert D. Allen | Senior Vice President-Research & Development |
